Impact Factor
3.31
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.89
424 total citations
h5-index
24
h5 depth signal
Cited share
72.4%
110 of 152
Total citations
424
Citation footprint
Metric signal
2.65
External metric anchor
Self-citation
5.7%
24 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
144
Italy
119
United Kingdom
88
Netherlands
76
France
51
Citing Fields of Research
Nervous System Disorders
406
Neuromuscular Disorders
275
Auto-Inflammatory Disorders
54
Cancer Drugs
28
Neurodegenerative Disorders
26
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,127
Articles tracked across the journal lifetime
Indexed publication set
152
110 cited publications
Last 12 months
111
9.3 publications/month
Open access share
48.6%
54 OA publications in the last year
Leading citing country
United States
144 citing publications
Leading citing field
Nervous System Disorders
406 citing publications
Latest tracked publication
30 September 2026
10 recent records available
Coverage & Indexing History
v1n1, 1996-
v1n1, 1996-
Active Coverage
Research Focus & Classification
Indexed Subjects
Nervous System Disorders
Neuromuscular Disorders
Issuing & Sponsoring Bodies
Contributor
Peripheral Nerve Society
Broad Categories
Neurology
Neuromuscular Disorders
Nervous System Disorders
MeSH Descriptors
Peripheral Nervous System Diseases
Peripheral Nervous System
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1111/jns.70175
Open DOI
Rituximab With or Without Chemotherapy for Anti‐ MAG Neuropathy: A Retrospective Multicenter Real‐World Study
Background and Aims: In anti‐myelin‐associated glycoprotein (MAG) neuropathy, the efficacy of rituximab (RTX) is not demonstrated in randomized controlled trials. Combinations of RTX with conventional chemotherapy (immunochemotherapy, IC...
02
03
04
DOI 10.1111/jns.70173
Open DOI
Cardiovascular Autonomic Neuropathy in Charcot–Marie–Tooth Disease: A Genotype‐Stratified Study of PMP22 Duplication and GJB1 Mutation Carriers
Background and Aims: Data on cardiovascular autonomic neuropathy (CAN) are sparse in Charcot–Marie–Tooth disease. We aimed to determine the prevalence of CAN in CMT1A and CMTX1 and its associations with neuropathy severity and heart rate...
05
DOI 10.1111/jns.70172
Open DOI
Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double‐Blinded, Placebo‐Controlled Crossover Study
Background and Aims: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an immune‐mediated neuropathy that may cause persistent disability despite immunoglobulin treatment. Ion channel dysfunction has been demonstrated in CIDP, ...
06
DOI 10.1111/jns.70174
Open DOI
Newly Developing IgM Anti‐ GD1a / GD1b Ganglioside IgM Monoclonal Gammopathy in a Patient With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Background and Aims: Chronic inflammatory demyelinating neuropathy (CIDP) is a rare, immune‐mediated neuropathy that is distinct from other immune‐mediated, paraneoplastic, and paraproteinemic neuropathies that may have overlapping clini...
07
DOI 10.1111/jns.70129
Open DOI
Issue Information
08
09
10
Bibliographical & Catalog Notes
Supplements accompany some issues.
Also issued online.
Official journal of: the Peripheral Nerve Society, <2010->
Vol. 1, no. 1 (1996)19990106 Notice published Printed on acid-free paper